Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

A Promising Approach to Translational Research on Stem Cells for Parkinson’s Disease

By Mary Ann Liebert, Inc./Genetic Engineering News | July 23, 2018

A major factor underlying Parkinson’s Disease (PD) pathology is the loss of dopamine neurons in the substantia nigra, and thus current therapies often aim to restore dopamine signaling. However, these treatments are not curative. The most promising approach for truly reversing disease progress involves the replacement of the specific dopamine neurons that have been lost, and this is the focus of a special issue on Parkinson’s Disease, published in Stem Cells and Development, a peer-reviewed journal published by Mary Ann Liebert, Inc., publishers. The special issue is available free on the Stem Cells and Development website until August 24, 2018.

In “Autologous Induced Pluripotent Stem Cell-Derived Neurons to Treat Parkinson’s Disease ,”Jeanne F. Loring, PhD, the Scripps Research Institute (La Jolla, CA), discusses impending clinical trials involving stem cell-derived therapies for treating PD. Loring contends that individualized dopamine neurons differentiated from patient-specific induced pluripotent stem cells (iPSCs) hold the greatest promise for effective treatment. The downside of the iPSC approach is the associated cost, but Loring points to the success of individualized immunotherapy for cancer treatment to bolster her case.

In “Novel Approach to Stem Cell Therapy in Parkinson’s Disease.” Russell Kern, International Stem Cell Corporation (CA), Andrew Evans, Royal Melbourne Hospital (VIC, Australia), and colleagues present a differing view on the ideal approach. Instead of patient-specific neurons, they use parthenogenetic (from chemically induced unfertilized oocytes)-derived neural stem cells. Advantages of this approach include the evasion of ethical issues surrounding embryos (also true with iPSCs), a reduced number of de novo mutations compared with iPSCs, and apparently low immunogenicity due to HLA-G expression, which is thought to play a role in immune tolerance during pregnancy.

“The understandable excitement generated by recent successful phase 1 clinical trials in the treatment of Parkinson’s disease (PD) is tempered with worldwide concern for the safe translation of stem cell research to an effective treatment for this terrible disease and other neurological conditions,” says Editor-in-Chief Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI. “The research in this special issue reflects the responsible advancement of cell therapy for PD.”

Warning: Cannot modify header information – headers already sent by (output started at /app/docroot/includes/common.inc:2777) in /app/docroot/includes/bootstrap.inc on line 1486


Filed Under: Neurological Disease

 

Related Articles Read More >

FDA expands Vizamyl label to include quantification and therapy monitoring, creating new competitive edge
AbbVie announces head-to-head results challenging migraine treatment status quo
Human study tracks brain’s glymphatic flow in real time, opening Alzheimer’s drug avenues
An 8-year-old patient with gangliosidosis demonstrates improved mobility, walking unassisted on a soccer field after treatment with N-acetyl-L-leucine. (Still from video footage; parental consent obtained for use).
Modified amino acid approved for Niemann–Pick shows promise in early Parkinson’s research
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE